In this issue:
SCT using an anti-CD117 antibody in Fanconi anaemia
Dose-optimised recombinant human TPO vs. eltrombopag for ITP
Anti-CD38 monoclonal antibody (CM313) for primary ITP
RGI-2001 for acute GVHD prophylaxis after allogeneic SCT
Elranatamab for relapsed/refractory AL amyloidosis
Venetoclax monotherapy for Waldenström macroglobulinaemia: long-term follow-up
Clinically significant EVH in PNH treated with ravulizumab or eculizumab
Pirfenidone for chronic GVHD-related bronchiolitis obliterans syndrome
Post-SCT DLIs for preventing acute myeloid leukaemia/myelodysplastic syndrome haematological relapse
Allogeneic SCT for relapsed/refractory B-cell non-Hodgkin lymphoma: long-term outcomes
Please login below to download this issue (PDF)